AAAAAA
Results:
1-21
|
Results: 21
Authors:
KREUSER ED
SZELENYI H
HOHENBERGER P
LOCHS H
HABBOUBI N
OSTER W
THIEL E
BERDEL WE
Citation: Ed. Kreuser et al., A PHASE-II TRIAL OF TRIMETREXATE (TMTX), 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) IN UNTREATED PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA, European journal of cancer, 33, 1997, pp. 755-755
Authors:
BUNTZEL J
KUTTNER K
RUSSELL L
OSTER W
SCHUTH J
GLATZEL M
Citation: J. Buntzel et al., SELECTIVE CYTOPROTECTION BY AMIFOSTINE (A) IN THE TREATMENT OF HEAD AND NECK-CANCER WITH SIMULTANEOUS RADIOCHEMOTHERAPY (RCT), European journal of cancer, 33, 1997, pp. 852-852
Authors:
CVITKOVIC F
MAHJOUBI R
OSTER W
HABBOUBI N
MITA M
VANNETZEL JM
Citation: F. Cvitkovic et al., TRIMETREXATE (TMTX) MODULATION OF 5-FLUOROURACIL LEUCOVORIN (B-FU/LCV) IN UNTREATED HEAD AND NECK-CANCER/, European journal of cancer, 33, 1997, pp. 863-863
Authors:
FULDA S
OSTER W
BERTHOLD F
Citation: S. Fulda et al., EFFECTS OF WR-2721 (AMIFOSTINE) AND ITS METABOLITE WR-1065 ON THE ANTIPROLIFERATIVE ACTIVITY OF CHEMOTHERAPEUTIC-AGENTS ON NEUROBLASTOMA-CELLS IN-VITRO, Anti-cancer drugs, 8(1), 1997, pp. 34-41
Authors:
RUSTIN GJS
NELSTROP AE
CRAWFORD M
LEDERMANN J
LAMBERT HE
COLEMAN R
JOHNSON J
EVANS H
BROWN S
OSTER W
Citation: Gjs. Rustin et al., PHASE-II TRIAL OF ORAL ALTRETAMINE FOR RELAPSED OVARIAN-CARCINOMA - EVALUATION OF DEFINING RESPONSE BY SERUM CA125, Journal of clinical oncology, 15(1), 1997, pp. 172-176
Authors:
BORSI JD
CSAKI C
FERENCZ T
OSTER W
Citation: Jd. Borsi et al., ADMINISTRATION OF ETHYOL (AMIFOSTINE) TO A CHILD WITH MEDULLOBLASTOMATO AMELIORATE HEMATOLOGICAL TOXICITY OF HIGH-DOSE CARBOPLATIN, Anti-cancer drugs, 7(1), 1996, pp. 121-126
Authors:
ETIENNE MC
OSTER W
MILANO G
Citation: Mc. Etienne et al., DEVELOPMENT AND VALIDATION OF A CHIRAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY FOR ROGLETIMIDE AND ROGLETIMIDE-N-OXIDE ISOMERS IN PLASMA, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 343-348
Authors:
ANDERSON H
MERCER V
RUSSELL L
OSTER W
THATCHER N
Citation: H. Anderson et al., A PHASE-III RANDOMIZED STUDY OF CARBOPLATIN AND AMIFOSTINE VS CARBOPLATIN AND G-CSF IN PATIENTS WITH INOPERABLE NONSMALL CELL LUNG-CANCER, Blood, 88(10), 1996, pp. 1387-1387
Authors:
BUNTZEL J
GLATZEL M
KUTTNER K
SCHEFFLER B
OSTER W
FROHLICH F
Citation: J. Buntzel et al., ETHYOL(R) (AMIFOSTINE) PROVIDES MULTILINEAGE HEMATOPROTECTION AND PROTECTION AGAINST NONHEMATOLOGIC TOXICITIES INDUCED BY RADIOCHEMOTHERAPY(RCT) OF HEAD AND NECK-CANCER, Blood, 88(10), 1996, pp. 1781-1781
Authors:
PLANTING AST
VERMORKEN JB
CATIMEL G
DEMULDER PHM
DEGRAEFF A
OSTER W
VERDONK HER
Citation: Ast. Planting et al., RANDOMIZED PHASE-II STUDY OF WEEKLY CISPLATIN WITH OR WITHOUT AMIFOSTINE IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER, European journal of cancer, 31A, 1995, pp. 392-392
Authors:
FACCHINI T
BELPOMME D
KEMP G
ROSE P
ROULLET B
PHILLIPS P
SCHEFFLER BJ
OSTER W
CAPIZZI RL
SCHEIN PS
Citation: T. Facchini et al., AMIFOSTINE (AMI) SELECTIVELY PROTECTS AGAINST CUMULATIVE TOXICITIES OF CYCLOPHOSPHAMIDE (C) AND CISPLATIN (P), European journal of cancer, 31A, 1995, pp. 500-500
Authors:
CAPIZZI RL
SCHEFFLER BS
OSTER W
HABBOUBI N
SCHEIN PS
Citation: Rl. Capizzi et al., AMIFOSTINE REDUCES CUMULATIVE CISPLATIN NEPHROTOXICITY, European journal of cancer, 31A, 1995, pp. 577-577
Authors:
VERMORKEN JB
PUNT CJA
EELTINK CM
VANMAANEN L
OSTER W
VANHOUTEN MD
VANDERVIJGH WJF
Citation: Jb. Vermorken et al., BONE-MARROW PROTECTION BY AMIFOSTINE (AMI) IN PATIENTS TREATED WITH CARBOPLATIN (CARBO) - A PHASE-I STUDY, European journal of cancer, 31A, 1995, pp. 962-962
Authors:
CUVIER C
ARDAVANIS A
EXTRA JM
ESPIE M
OSTER W
MARTY M
Citation: C. Cuvier et al., PRELIMINARY-RESULTS OF A RANDOMIZED STUDY OF 1 VS 2 910 MG M/SQM DOSES OF AMIFOSTINE IN HIGH-RDI CYCLOPHOSPHAMIDE (CPM)-EPIRUBICIN (EDOX) IN PATIENTS WITH HIGH-RISK BREAST-CARCINOMA/, European journal of cancer, 31A, 1995, pp. 971-971
Authors:
OSTER W
SCHEFFLER B
CAPIZZI R
SCHEIN P
Citation: W. Oster et al., AMIFOSTINE - PROTECTION FROM HEMATOTOXICITY AND NEPHROTOXICITY INDUCED BY CHEMOTHERAPY, European journal of cancer, 31A, 1995, pp. 83-83
Authors:
CAPIZZI RL
OSTER W
Citation: Rl. Capizzi et W. Oster, PROTECTION OF NORMAL TISSUE FROM THE CYTOTOXIC EFFECTS OF CHEMOTHERAPY AND RADIATION BY AMIFOSTINE - CLINICAL-EXPERIENCES, European journal of cancer, 31A, 1995, pp. 8-13
Authors:
OSTER W
HABBOUBI N
SCHEFFLER B
CAPIZZI R
SCHEIN P
Citation: W. Oster et al., AMIFOSTINE - A NEWLY DEVELOPED ENTITY FOR CHEMOPROTECTION (PROTECTIONFROM HEMATO, NEPHROTOXICITY, OTOTOXICITY AND NEUROTOXICITY), Experimental hematology, 23(8), 1995, pp. 843-843
Authors:
BETTICHER DC
ANDERSON H
RANSON M
MEELY K
OSTER W
THATCHER N
Citation: Dc. Betticher et al., CARBOPLATIN COMBINED WITH AMIFOSTINE, A BONE-MARROW PROTECTANT, IN THE TREATMENT OF NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II STUDY, British Journal of Cancer, 72(6), 1995, pp. 1551-1555
Authors:
JODRELL DI
OSTER W
KERR DJ
CANNEY PA
YOSEF H
STEWARD WP
KAYE SB
CASSIDY J
Citation: Di. Jodrell et al., A PHASE I-II STUDY OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID (PALA) ADDEDTO 5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED COLORECTAL-CANCER, European journal of cancer, 30A(7), 1994, pp. 950-954
Authors:
LINK H
BRUNE T
HUBNER G
DIEDRICH H
FREUND M
STOLL M
PEEST D
EBELL W
BETTONI C
OSTER W
NICOLAY U
HEINRICHS H
Citation: H. Link et al., EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Annals of hematology, 67(4), 1993, pp. 169-173
Authors:
LUBBERT M
OSTER W
KNOPF HP
MCCORMICK F
MERTELSMANN R
HERRMANN F
Citation: M. Lubbert et al., N-RAS GENE ACTIVATION IN ACUTE MYELOID-LEUKEMIA - ASSOCIATION WITH EXPRESSION OF INTERLEUKIN-6, Leukemia, 7(12), 1993, pp. 1948-1954
Risultati:
1-21
|